INOVIO Pharmaceuticals

INOVIO Collaborates with GuardRX, Geneva University Hospitals for Heterologous Booster Clinical Trial of Ebola DNA Vaccine Candidate

PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) announced that several volunteers have been recently dosed with its DNA-based, intradermal Ebola vaccine candidate, INO-4201, as part of a randomized, placebo-controlled, Phase …

INOVIO Collaborates with GuardRX, Geneva University Hospitals for Heterologous Booster Clinical Trial of Ebola DNA Vaccine Candidate Read More